JP2023524207A5 - - Google Patents

Info

Publication number
JP2023524207A5
JP2023524207A5 JP2022564532A JP2022564532A JP2023524207A5 JP 2023524207 A5 JP2023524207 A5 JP 2023524207A5 JP 2022564532 A JP2022564532 A JP 2022564532A JP 2022564532 A JP2022564532 A JP 2022564532A JP 2023524207 A5 JP2023524207 A5 JP 2023524207A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
cycloalkyl
optionally substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524207A (ja
JP7751165B2 (ja
Filing date
Publication date
Priority claimed from GBGB2005852.5A external-priority patent/GB202005852D0/en
Application filed filed Critical
Publication of JP2023524207A publication Critical patent/JP2023524207A/ja
Publication of JP2023524207A5 publication Critical patent/JP2023524207A5/ja
Application granted granted Critical
Publication of JP7751165B2 publication Critical patent/JP7751165B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564532A 2020-04-22 2021-04-22 Nrf2活性化剤としてのテトラヒドロイソキノリン化合物 Active JP7751165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005852.5 2020-04-22
GBGB2005852.5A GB202005852D0 (en) 2020-04-22 2020-04-22 Therapeutic compounds
PCT/GB2021/050975 WO2021214472A1 (en) 2020-04-22 2021-04-22 Tetrahydroisoquinoline compounds as nrf2 activators

Publications (3)

Publication Number Publication Date
JP2023524207A JP2023524207A (ja) 2023-06-09
JP2023524207A5 true JP2023524207A5 (https=) 2024-04-09
JP7751165B2 JP7751165B2 (ja) 2025-10-08

Family

ID=70859963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564532A Active JP7751165B2 (ja) 2020-04-22 2021-04-22 Nrf2活性化剤としてのテトラヒドロイソキノリン化合物

Country Status (16)

Country Link
US (1) US20230159511A1 (https=)
EP (1) EP4139295B1 (https=)
JP (1) JP7751165B2 (https=)
KR (1) KR20230004722A (https=)
CN (1) CN115667242B (https=)
AR (1) AR121913A1 (https=)
AU (1) AU2021258539A1 (https=)
BR (1) BR112022021370A2 (https=)
CA (1) CA3174360A1 (https=)
ES (1) ES3031970T3 (https=)
GB (1) GB202005852D0 (https=)
IL (1) IL297440A (https=)
MX (1) MX2022013396A (https=)
PH (1) PH12022552773A1 (https=)
WO (1) WO2021214472A1 (https=)
ZA (1) ZA202211464B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004566A (es) 2018-10-22 2021-06-08 C4X Discovery Ltd Compuestos terapeuticos.
US20240424112A1 (en) 2021-10-25 2024-12-26 C4X Discovery Limited Tetrahydroisoquinoline compounds that are keap1 binders.
PE20241779A1 (es) * 2022-01-07 2024-09-03 Chugai Pharmaceutical Co Ltd Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del nrf2
WO2024130411A1 (en) * 2022-12-21 2024-06-27 Variational Ai Inc. Protease inhibitors and methods of using same
WO2024262491A1 (ja) * 2023-06-19 2024-12-26 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物の結晶
EP4596534A1 (en) * 2024-01-31 2025-08-06 University of Copenhagen Noncovalent small-molecule inhibitors of the keap1-nrf2 interaction
WO2025237912A1 (en) 2024-05-13 2025-11-20 Astrazeneca Ab Keap1 inhibitors for use in the treatment of bronchiectasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
CA2988373A1 (en) * 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
MX2021004566A (es) 2018-10-22 2021-06-08 C4X Discovery Ltd Compuestos terapeuticos.

Similar Documents

Publication Publication Date Title
JP2023524207A5 (https=)
US10590113B2 (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
JP7792915B2 (ja) Cd38阻害薬
US20090239845A1 (en) Pyrazole compounds as prostaglandin receptors ligands
JP7476216B2 (ja) ファルネソイドx受容体モジュレータとしての置換二環式化合物
ES2791340T3 (es) Derivado de urea o sal farmacológicamente aceptable del mismo
US9783530B2 (en) Factor Xla inhibitors
HRP20231306T1 (hr) Terapeutski spojevi
RU2021133444A (ru) Производные бензимидазола в качестве модуляторов ror-гамма
WO2010051245A1 (en) Benzimidazole and aza-benzimidazole carboxamides
US8367679B2 (en) Biaryl carboxamides
EP3303330A1 (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
JP2011500563A (ja) ジフェニル置換されたシクロアルカン
JP2015506349A (ja) 非全身性tgr5アゴニスト
JP2024525900A (ja) グルカゴン様ペプチド-1受容体モジュレーター及びその使用
EP3704106A1 (en) Alkene compounds as farnesoid x receptor modulators
JP2023524206A5 (https=)
JP2010518146A (ja) ベンゾフラン化合物
US12344597B2 (en) Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis
WO2014029722A1 (en) Novel pyridine derivatives
TWI881587B (zh) 類木瓜蛋白酶(PLpro)抑制劑
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
EA040901B1 (ru) Алкокси-замещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
HK40077288B (zh) 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
HK1232215B (zh) 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物